Cytochrome P450 inhibitor. Inhibits several cytochrome P450 enzymes including aromatase (CYP19) and retinoic acid 4-hydroxylase (CYP26). Blocks retinoic acid metabolism (retinoic acid metabolism blocking agent, RAMBA). Displays antitumor activity against androgen-dependent and independent rat prostate carcinomas.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo.
Van Wauwe et al.
Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases.
Njar et al.
Effects of liarozole fumarate (R85246) in combination with tamoxifen on N-methyl-N-nitrosourea (MNU)-induced mammary carcinoma and uterus in the rat model.
Goss et al.
BMC Cancer, 2007;7:26
The citations listed below are publications that use Tocris products. Selected citations for Liarozole dihydrochloride include:
Showing Results 1 - 2 of 2